News Room
News Room
News Room
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late‑stage program in a high-need, specialized area of neuroscience expands Teva’s innovative medicines pipeline, aligns with commercial strengths and [...]
First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy
Study opens pathway to investigational therapy for patients with Tourette syndrome who have exhausted approved treatments CHICAGO — March 9, 2026 — Emalex [...]
Biotech Innovation Update
Last year, Paragon Biosciences and its portfolio companies advanced transformative science with a singular mission: to accelerate breakthroughs that improve lives. Across [...]
Groundbreaking Achievements and Pivotal Milestones for Paragon and its Portfolio Companies
In 2024, Paragon and its portfolio companies achieved remarkable research and development progress, driving innovative solutions for patients with critical unmet needs. [...]
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Topline data from Phase 3 study in patients with Tourette syndrome shows statistical significance between ecopipam and placebo for both the primary efficacy endpoint [...]
Emalex Biosciences Named “Neuroscience Therapeutics Company Of The Year” by BioTech Breakthrough
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industries CHICAGO, November 19, 2024 – Emalex Biosciences was named “Neuroscience [...]
